Sonablate® HIFU Prostate Tissue Ablation Performed on First San Francisco Patient

Share Article

Michael J. Lazar, MD is the first physician to offer the recently FDA-cleared Sonablate® prostate tissue ablation procedure for men in San Francisco, CA.

Sonablate trans-rectal HIFU probe
"It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users” - Dr. Michael Lazar

SonaCare Medical, LLC announces that a second location in the United States has performed a prostate tissue ablation procedure using the company’s Sonablate® High Intensity Focused Ultrasound (HIFU) technology which FDA granted regulatory authorization for on October 9, 2015.

This Sonablate® procedure, the first commercial focused ultrasound ablation performed on the west coast, was performed by Dr. Michael Lazar, who has been working with HIFU patients since 2007. Dr. Lazar has held a long-standing relationship with SonaCare Medical, having performed a large number of HIFU ablative procedures outside the United States through SonaCare Medical's subsidiary company, International HIFU, for which he has served as a proctor and medical director. Dr. Lazar has been a strong advocate for having this technology accessible to American men inside the United States. "It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users,” said Lazar.

The procedure was performed at the San Francisco Surgery Center (SFSC) in downtown San Francisco near Union Square. According to Kevin Wienke, administrator of the San Francisco Surgery Center, “The center is proud to be able to receive one of the first Sonablate® HIFU systems in the country and to partner with Dr. Lazar and HIFU Prostate Services to offer our patients a viable option for prostate tissue ablation.”

SonaCare Medical's CEO, Dr. Mark Carol, remarks that "We are excited that Dr. Lazar has been able to establish a HIFU program in a highly accessible surgery center. The combination of a fast procedure and an easy to access out-patient center represents a patient friendly advance over traditional prostate procedure options."

Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate® technology has been used around the world on nearly 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S.

About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

For additional information, visit


SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)SonaCareMedical(dot)com

Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Erica Griffith
Follow >
Visit website